"Diphosphonates" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Organic compounds which contain P-C-P bonds, where P stands for phosphonates or phosphonic acids. These compounds affect calcium metabolism. They inhibit ectopic calcification and slow down bone resorption and bone turnover. Technetium complexes of diphosphonates have been used successfully as bone scanning agents.
| Descriptor ID |
D004164
|
| MeSH Number(s) |
D02.705.429.500
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Diphosphonates".
Below are MeSH descriptors whose meaning is more specific than "Diphosphonates".
This graph shows the total number of publications written about "Diphosphonates" by people in this website by year, and whether "Diphosphonates" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2009 | 2 | 0 | 2 |
| 2011 | 1 | 0 | 1 |
| 2012 | 2 | 1 | 3 |
| 2013 | 2 | 0 | 2 |
| 2014 | 0 | 1 | 1 |
| 2017 | 0 | 1 | 1 |
| 2021 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Diphosphonates" by people in Profiles.
-
Prognosis of Patients With Early Breast Cancer Receiving 5 Years vs 2 Years of Adjuvant Bisphosphonate Treatment: A Phase 3 Randomized Clinical Trial. JAMA Oncol. 2021 Aug 01; 7(8):1149-1157.
-
German Adjuvant Intergroup Node-positive Study (GAIN): a phase III trial comparing two dose-dense regimens (iddEPC versus ddEC-PwX) in high-risk early breast cancer patients. Ann Oncol. 2017 Aug 01; 28(8):1803-1810.
-
Prognostic relevance of disseminated tumour cells from the bone marrow of early stage breast cancer patients - results from a large single-centre analysis. Eur J Cancer. 2014 Oct; 50(15):2550-9.
-
Influence of zoledronic acid on disseminated tumor cells in bone marrow and survival: results of a prospective clinical trial. BMC Cancer. 2013 Oct 15; 13:480.
-
Bisphosphonates modulate vital functions of human osteoblasts and affect their interactions with breast cancer cells. Breast Cancer Res Treat. 2013 Jul; 140(1):35-48.
-
Antitumor activity of zoledronic acid in primary breast cancer cells determined by the ATP tumor chemosensitivity assay. BMC Cancer. 2012 Jul 23; 12:308.
-
Attenuated BMP1 function compromises osteogenesis, leading to bone fragility in humans and zebrafish. Am J Hum Genet. 2012 Apr 06; 90(4):661-74.
-
Influence of zoledronic acid on disseminated tumor cells in primary breast cancer patients. Ann Oncol. 2012 Sep; 23(9):2271-2277.
-
Cytotoxicity of the new antimetabolite-bisphosphonate (5-FdU-alendronate) in comparison to standard therapeutics on breast and ovarian cancer cell lines in the ATP tumor chemosensitivity assay. Invest New Drugs. 2012 Aug; 30(4):1750-5.
-
Bisphosphonate-associated osteonecrosis of the jaw in breast cancer patients: recommendations for prevention and treatment. Breast. 2009 Aug; 18(4):213-7.
MeSH information
